Anthem Bioscience IPO Listing: GMP Indicates 29.65% Potential Gain, Subscription Recap, and Key Details.

Anthem Bioscience is set to debut on Dalal Street on July 21, with shares trading at a premium of Rs 169 in the grey market, indicating an estimated listing price of around Rs 739 per share. The IPO was subscribed 63.86 times overall, with QIBs subscribing 182.65 times, NIIs subscribing 42.35 times, and retail investors subscribing 5.64 times. Anthem Biosciences is a tech-driven contract research and manufacturing company based in Bengaluru, offering end-to-end services across the drug lifecycle.

Anthem Biosciences, a tech-driven contract research and manufacturing company based in Bengaluru, is set to make its market debut on Dalal Street on July 21. The company has generated significant interest with its IPO, which is slated to be one of the most anticipated listings of the year.

The grey market premium (GMP) for Anthem Biosciences shares is trading at Rs 169, indicating an estimated listing price of around Rs 739 per share [1]. This premium suggests a high level of investor confidence and a potential for significant gains on the first day of trading.

The IPO has been overwhelmingly subscribed, with the issue receiving bids worth Rs 2,638 crore, or 1.05 times the shares on offer [2]. This high demand was driven by strong participation from all categories of investors. Qualified Institutional Buyers (QIBs) subscribed 182.65 times their allotted portion, while Non-Institutional Investors (NIIs) subscribed 42.35 times and retail investors subscribed 5.64 times [3].

Anthem Biosciences offers end-to-end services across the drug lifecycle, catering to global clients in the Contract Research Organisation (CRO) and Contract Development and Manufacturing Organisation (CRDMO) space. The company has two manufacturing facilities in Bengaluru and provides services such as early-stage drug discovery, drug efficacy testing, and the manufacture of Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars [4].

The IPO is expected to close on Wednesday, and the company will not receive any funds from the issue, as it is an offer-for-sale (OFS) [3]. The proceeds will go to the selling shareholders, including anchor investors such as Abu Dhabi Investment Authority, Norway's Norges Bank, France's Societe Generale, HDFC Mutual Fund, and ICICI Prudential AMC [2].

Anthem Biosciences' strong subscription and the high grey market premium indicate that the company is well-positioned to make a positive impression on its listing day. However, market conditions and investor sentiment during the opening bell will ultimately determine the success of the debut. Investors will be watching closely to see if Anthem Biosciences delivers on its promising prospects.

References:
[1] https://www.financialexpress.com/market/ipo-news-anthem-bioscience-ipo-listing-today-big-debut-or-flat-start-heres-what-gmp-indicates-3920947/
[2] https://www.thehindubusinessline.com/markets/stock-markets/indian-drugmaker-anthem-biosciences-395-million-ipo-fully-subscribed-on-day-two/article69814094.ece
[3] https://www.financialexpress.com/market/ipo-news-anthem-biosciences-ipo-get-3-28x-subscription-on-day-2nbsp-3915386/
[4] https://www.reuters.com/business/healthcare-pharmaceuticals/indias-anthem-biosciences-395-million-ipo-fully-subscribed-day-two-2025-07-15/